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ABSTRACT 
Objectives: The efficacy of transcutaneous electrical nerve stimulation (TENS) for pain relief has not been 
reliably established.  Inconclusive findings could be due to inadequate TENS delivery and inappropriate 
outcome assessment.  Electronic monitoring devices were used to determine patient compliance with a 
TENS intervention and outcome assessment protocol, to record pain scores before, during and after TENS 
and measure electrical output settings. 
Methods: Patients with chronic back pain consented to use TENS daily for two weeks and to report pain 
scores before, during and after 1-hour treatments.  A ≥30% reduction in pain scores was used to classify 
participants as TENS-responders. Electronic monitoring devices ‘TLOG’ and ‘TSCORE’ recorded time and 
duration of TENS-use, electrical settings and pain scores.  
Results: Forty-two patients consented to participate.  1/35 (3%) patients adhered completely to the TENS-
use and pain score reporting protocol.  14/33 (42%) were TENS responders according to electronic pain 
score data.  Analgesia onset occurred within 30-60 minutes for 13/14 (93%) responders.  It was not possible 
to correlate TENS amplitude, frequency or pulse width measurements with therapeutic response. 
Discussion: Findings from TENS research studies depend on the timing of outcome assessment; pain should 
be recorded during stimulation. TENS device sophistication might be an issue and parameter restriction 
should be considered. Careful protocol design is required to improve adherence and monitoring is necessary 
to evaluate the validity of findings. This observational study provides objective evidence to support concerns 
about poor implementation fidelity in TENS research.   
 
Key Words: Transcutaneous electrical nerve stimulation; pain measurement; electronic data capture; 
reproducibility; data collection 
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INTRODUCTION 
     Transcutaneous electrical nerve stimulation (TENS) is a widely-used, patient-directed analgesic 
technique but randomised controlled trials (RCTs) have been inconclusive (1).  This could be due to poor 
‘implementation fidelity’, the extent to which interventions are delivered and assessed as intended (2).  
Inappropriate timing of outcome assessments, inadequate patient compliance and suboptimal dosing could 
reduce reported TENS efficacy (3).   
TENS analgesia has rapid onset and offset (4, 5, 6, 7) suggesting that pain should be reported during 
stimulation.  However, only 4/41 RCTs (8, 9, 10, 11) in Cochrane systematic reviews (12, 13, 14) measure 
pain during TENS.  Retrospective weekly pain report has been shown to be higher than averaged daily pain 
scores, emphasising the need for real-time reporting (15).  Retrospective recall can also overestimate TENS-
use (6). TENS dosing depends on stimulation intensity, frequency and duration.  Strong, comfortable 
paraesthesia gives clinical benefit (3) and increases mechanical pain threshold in healthy participants, but 
stimulation at the sensory threshold does not (16).  Implementation fidelity also depends on outcome 
assessment, but paper pain diaries can be unreliable (17) and electronic diaries require competent users, 
expensive hardware and software. 
     Two electronic data-logging devices (Figure 1) have been developed: ‘TLOG’ records time, date and 
duration of TENS treatments and stimulus frequency, pulse duration and amplitude.  It attaches to a 
commercially-available TENS machine and its use requires no action by patients. ‘TSCORE’ is a 0-10 
numerical rating scale (NRS) comprising 11 buttons spaced 1cm apart in a plastic enclosure; pressing a 
button records pain score, time and date.  TSCORE is a simple-to-use, single-function device for instant use; 
no computer skills are required and battery life is several months. The devices’ internal clocks allow pain 
report to be time-linked to TENS-use; data are stored for download to computer.  TLOG and TSCORE data 
have been shown to be equivalent to paper diary data (18). Electronic monitoring has been used to record 
treatment duration, pain scores and the intensity of TENS with frequency and pulse-duration fixed (19). 
However pain was not reported during stimulation. The temporal relationship between TENS-use and pain 
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report has been investigated using retrospective questionnaires (6) and single researcher-administered 
treatments (4, 5).   We are not aware of any studies using electronic devices to record pain scores before, 
during and after TENS and monitor output settings and compliance when users are asked to titrate TENS to 
provide strong comfortable paraesthesia.  We report an observational study using devices to monitor 
compliance with TENS intervention and outcome assessment protocols, pain intensity before, during and 
after TENS and electrical parameters selected by patients.   
MATERIALS AND METHODS 
Participants 
     Participants (≥ 18 years) were outpatients with chronic low back pain (≥3 months’ duration attending 
physiotherapy or chronic pain clinics at the University Hospitals of Leicester (UHL) NHS Trust.  Patients were 
pre-screened by clinic staff for non-specific low back pain and a willingness to trial TENS therapy in addition 
to their existing medication. No threshold for initial pain intensity was set because this observational work was 
a secondary part of a study designed primarily to test equivalence of paper and electronic data collection (18). 
Participants were of any ethnic origin but fluent in English. Those with illiteracy, learning difficulties or 
contraindications for use of TENS machines, as described in guidelines for the clinical use of electro-
physical agents (20), were excluded. Invitation letters and patient information sheets were given to all eligible 
patients by clinic staff and interested patients were asked to return a reply slip to the research team.  Invitation 
letters were distributed to patients until 42 patients had consented to participate. The study was approved by 
the Leicestershire, Northamptonshire and Rutland research ethics committee. Participants were reimbursed for 
travelling costs.  
Sample size 
     Data for the current study were collected during a TLOG and TSCORE validation study (18), which used 
Bland Altman limits of agreement analysis, (21). Sample size was calculated using Bland and Altman’s 
formula for determining limits of agreement between two measurement methods using a standard deviation of 
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1.28.  Based on a difference of ±1 on the 0-10 pain intensity numerical rating scale indicating ‘agreement’ 
between paper and TSCORE data, the required sample size was n = 40.   
Materials 
1. Fourteen commercially-available CE-marked TENS machines (‘COM-TENS’: Apex Medical 
Corporation, Taiwan, ROC), each with a battery-powered TLOG device attached by Velcro fastening. 
2. One pair of electrodes and spare 9 volt batteries for each participant.   
3. Fourteen TSCORE pain scoring devices.  Users press a button to record a pain score with time and date.  
A light confirms that the score has been logged. 
All TLOG and TSCORE devices were designed and built at UHL NHS Trust.  Before use, each device was 
tested and approved for use with UHL patients by the UHL Medical Physicist.  The TENS machine with 
TLOG device attached, a pair of electrodes and the TSCORE pain scoring device are shown in Fig. 1. 
 
 
Insert Fig. 1 (photo of TENS with TLOG attached and TSCORE) 
 
 
Procedure    
     All procedures carried out during this study were in accordance with the ethical standards required by the 
Leicestershire, Northamptonshire and Rutland research ethics committee and with the Helsinki Declaration of 
1975 (revised 1983).  Patients who responded to the invitation letter were telephoned by a researcher who 
assessed suitability for the study and invited eligible patients to attend study visit 1.  After giving written 
informed consent participants were given a study TENS machine with TLOG attached.  They were given 
full verbal instructions and were shown how to use the TENS machine with one output channel and one pair 
of electrodes.  Patients were asked to use TENS for one hour per day for two weeks and to record pain 
scores at prescribed time intervals before, during and after each one-hour TENS treatment. 
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Patients were expected to use TENS daily even if they were not experiencing pain; however informed 
consent ensured that patients could leave the study at any time without explanation. 
 Patients were shown how to adjust frequency, pulse duration and intensity settings on the TENS machine 
and were asked to do this at each treatment session in order to achieve pain relief and/or a comfortable 
TENS sensation. Emphasis was given to explaining how to achieve a strong but comfortable paraesthesia 
using the amplitude (intensity) setting. The range of pulse frequencies and pulse durations available to 
patients was 2-150Hz and 60-250 µs respectively.  The amplitude dial was marked 0-8, with 80V the 
maximum voltage. A monophasic rectangular pulse waveform was delivered to patients via two 5x5cm 
square reusable electrodes placed on the lower back, either side of the spine. Only 1 channel (2 electrodes) 
of the TENS machine was used for treatment since TLOG only contained hardware for processing a single 
channel. It would normally be possible for patients to use two channels, with independent intensity control, 
to target chronic low back pain that might not be well localised. A lead with a pair of electrodes attached 
was directly wired to TLOG/TENS machine channel one, no lead was provided for the second channel. 
Patients could only use channel one and were shown how to adjust the corresponding intensity dial.  The 
TENS machines had ‘burst’ and ‘modulation’ modes disabled for the study and users were restricted to 
using continuous mode only. To overcome sensory habituation (22), participants were told that if they felt 
that the stimulation sensation had decreased, they should increase the intensity setting, (23).  
The TSCORE device was demonstrated and patients were given a device so that they could practise 
recording pain scores.  They were asked to use it to report pain scores four times daily: (i) Just before 
starting a one-hour TENS treatment (‘baseline’); (ii) 30 minutes after starting TENS (‘TENS_30’); (iii) 60 
minutes after starting TENS (i.e. at the end of the one-hour treatment) (‘TENS_60’); (iv) 30 minutes after 
switching the TENS machine off (‘post_TENS’). Patients were asked if they had understood what they were 
being asked to do and were given detailed written instructions reiterating the verbal instructions already 
given. They were given the researcher’s telephone number and email address and were asked to contact the 
researcher if they had any queries.  Participants were advised to continue their usual medication regime 
throughout the study. The researcher telephoned patients after one week to troubleshoot and to remind 
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patients of the need to adhere to the protocol.  Approximately two weeks after the first visit patients returned 
their equipment and medication diaries. Data were retrieved from TSCORE and TLOG devices and they 
were cleared and tested for re-issue. The associated TENS machine output levels were verified using an 
oscilloscope and a 1KΩ resistor test load. 
Statistical analysis 
     Statistical analyses were performed using PASW Statistics 18 (SPSS Inc., Chicago, IL, USA) and 
Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA, USA). Participant characteristics were 
reported using descriptive statistics. Compliance with TENS implementation and pain score reporting 
protocols was calculated and analysed using descriptive statistics.   
Pain scores before, during and after TENS 
     For each individual, daily pain scores were averaged over the number of days for which data were 
available, to give mean pain scores for baseline, TENS_30, TENS_60 and post_TENS.  The percentage 
changes in mean pain scores from baseline to the three post-baseline time points were calculated for each 
patient. A ≥30% reduction in mean pain scores from baseline classified a patient as a TENS ‘responder’ at 
that time point, based on the minimum clinically important difference needed to indicate response to 
treatment being defined as ≥30% (24). Patients who reported an increase in mean pain scores from baseline 
or a reduction in pain scores <30% were ‘non-responders’ at that time-point.  Each patient’s maximum 
percentage change in mean pain scores from baseline was determined by comparing changes in pain scores 
at the three post-baseline time points.   
Electrical characteristics 
TLOG records the frequency, amplitude and width of the TENS pulse.  These output parameters are reported 
and discussed.  
RESULTS 
1. Participant characteristics and course through the study 
     Forty two patients with back pain of ≥ 3 months’ duration consented to participate in the study.  After 
consenting one patient was unable to understand how to use TENS and was excluded.  The mean age of 
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participants (n=41) was 52 years (range 23 to 80; 24 females (59%)).    Attrition in participant numbers and 
the course of all participants through the study is shown in Fig.2.  Two patients did not administer any study 
treatments: One person cited “lack of time” as the reason for not using TENS, while the other tried TENS 
for a short period and reported that it made the pain worse. 
 
 
 
Insert Fig. 2 (flow chart) here 
 
 
2. Compliance with TENS implementation protocol 
     Forty one participants were given a TENS machine with TLOG attached and asked to use it for one hour 
per day for 13 or 14 days.  Three TLOG devices failed to collect data due to faulty components; 
consequently TENS-use data were available for 38 patients.  The mean and SD of the duration of all study 
treatments were calculated for each patient.  Patients were considered to have adhered fully to the duration 
of treatments protocol if the mean of their daily treatment durations was 60±10 minutes with SD≤10 
minutes.  Table 1 shows compliance rates with the protocol for TENS usage pattern and daily duration of 
TENS treatments that participants consented to adhere to.  
 
 
Insert Table 1 here 
 
 
3. Compliance with TSCORE pain score reporting protocol 
(i) Compliance with prescribed number of pain reports  
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     Forty one participants were asked to use TSCORE to report pain at four prescribed time-points baseline, 
TENS_30, TENS_60  and post_TENS for 14 daily TENS treatments.   One TSCORE device failed due to a 
technical problem.  Forty participants had fully functioning TSCORE devices with which to report pain 
scores. Figure 3 shows the numbers of patients who reported pain scores at the four time points on ≥13 days, 
7-12 days and ≤6 days. 
 
 
 
Insert Fig. 3 (Number of patients reporting pain scores at any of four time points) here 
 
 
(ii) Overall compliance with required number of pain reports at all prescribed time points 
     The study protocol required 56 pain reports (4 time points x14 days) to be made using TSCORE. 14/40 
(35%) participants made more than 80% of the required pain reports; 11/40 (28%) made 50-80% and 15/40 
(38%) made less than half of the prescribed pain reports.  
    (iii) Compliance with prescribed timing of pain reports relative to TENS use 
     Further analyses time-linking TENS-use and pain report required both TLOG and TSCORE data for each 
participant.  6/41 (15%) did not have both TLOG and TSCORE data: 3 had faulty TLOG devices (1 of these 
patients did not use TSCORE); 1 had a faulty TSCORE device and 2 did not use TENS or TSCORE.  The 
remaining 35 participants had both TLOG and TSCORE data.  Table 2 shows compliance rates with the 
protocol for the timing of pain reports that participants consented to adhere to. 
 
Insert Table 2 here 
 
 
4. Overall compliance with TENS implementation AND pain score reporting protocols 
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     1/35 (3%) patients adhered fully to the study protocol for TENS-use and pain score reporting.  7/35 
(20%) had ‘good’ compliance in that they used TENS for 60±10 minutes for ≥ 13 days and reported pain at 
the prescribed times on all but 1-5 occasions. The remaining 27/35 (77%) adhered only partially to the study 
protocol, either using TENS on fewer days or for more or less than the prescribed treatment time, making 
fewer pain reports than required or reporting pain at times other than the prescribed time points.  
5. Identification of TENS responders and non-responders from TSCORE data 
     The mean (SD) baseline pain score of TSCORE-users (N=35) before their first TENS treatment was 5.2 
(2.2), (range 1-8).  2/35 participants reported baseline pain scores only, therefore changes in pain scores 
from 33 participants were used to classify them as TENS ‘responders’ or ‘non-responders’.  A ≥30% 
reduction in pain scores at any post-baseline time point defined ‘response’ to TENS. 14/33 (42%) 
participants were TENS responders of which 4/14(29%) complied with 1 hour/day for 13-14 day usage 
pattern.  Half of these responders (7/14) reported analgesia onset within 30±10 minutes and for 13/14 (93%) 
it occurred within 60±10 minutes.  1/14 (7%) responders experienced pain relief post-TENS only.  9/13 
participants who were responders during TENS, reported pain scores afterwards; all were responders at the 
post_TENS time point.  19/33 (58%) patients were classified as non-responders at all-time points, from their 
TSCORE data.  
6. Medication use 
     Of the 33 participants who could be classified as TENS-responders or non-responders, 12 (36%) did not 
use analgesic medication during the study of which 6/12 were responders and 6/12 were non-responders. 
Medication diaries were not returned by 2(6%) of participants. The remaining 19/33 (58%) adhered to their 
usual medication regime.  6/19 (32%) patients taking medication for analgesia used only 1 type of drug 
while 13/19 (68%) used a combination of drugs. No patients altered their drug doses or frequency of use 
during the study.   
7. TENS-use and electrical output parameters 
     Participants were asked to adjust electrical stimulation parameters to deliver a strong but comfortable 
paraesthesia. Of the 41 patients given TENS machines, 36 had data recorded by TLOG, which sampled the 
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electrical output signal every ten minutes.  13/36 (36%) patients selected only stimulus frequencies ≤100 Hz 
throughout the study and 20/36 (56%) used a wider range of frequencies including >100 Hz. In 3/36 (8%) 
data sets TLOG was not able to record any frequency data.  Peak amplitude measurements were available 
for 33/36(92%) of TLOG datasets and ranged from 0 to 58V.  There were problems associated with 
measuring the pulse duration of the TENS output waveform causing data recorded by TLOG to be 
unsuitable for further analyses; these issues are discussed in the next section.  Descriptive statistics regarding 
pain intensity and electrical characteristics were calculated. (See Table 3 and Fig.4, Supplemental Digital 
Content 1, which indicates the relationship between mean summed pain intensity scores and mean TENS 
voltage for responders and non- responders.) 
 
 
 
 
DISCUSSION 
     The use of electronic data monitoring in this observational study showed that patients did not adhere to 
the study protocol and self-administered TENS treatment protocol.  Bennett et al (3) expressed concerns 
regarding the extent to which TENS interventions are delivered and assessed as intended and this study 
provides evidence that there are grounds for such concerns. Johnson and Bjordal (25) identify TENS 
treatments that are too short, too infrequent or with inadequate technique, as causes of low fidelity leading to 
inconclusive research findings.  Our study shows that the use of electronic data monitoring is essential to 
validate the findings of studies where TENS is self-administered at home.   
     A surprising finding was the poor compliance with the study protocol given that patients were aware that 
their TENS-use and pain reporting was being monitored.  Only one participant adhered fully to instructions 
for both TENS machine-use and pain score reporting.  One possible explanation for poor compliance is that 
the requirement to use TENS daily for 1 hour for 2 weeks and to report 4 pain scores daily at specified time 
intervals was too demanding.  However, if this is the case, it raises concerns about the fidelity of more 
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demanding studies such as one requiring chronic pain patients to self-administer TENS for multiple sessions 
providing 168 hours of stimulation over 4 weeks (26).   
 
Failure to adhere to the prescribed daily usage pattern for TENS may have resulted from poor motivation in 
some patients who had initial pain scores as low as 1. These low scores could have been attributable to 
recently administered analgesia. Many clinical trials use a baseline pain score ≥4 as an eligibility criterion 
and failure to set such an inclusion criterion is a limitation of our study. However, limiting baseline scores at 
study enrolment might not appropriately reflect the variability of pain intensity prior to each TENS 
treatment. This demonstrates the need for robust recording methods to record pain intensity before, during 
and after TENS. This requirement could be applied to include studies that use other interventions.   
This observational work was a secondary part of a study designed primarily to test equivalence of paper and 
electronic data collection (18); consequently no threshold for initial pain intensity was set and no baseline 
pain history taken. Similarly we did not look at quality of life, pain with respect to activity and movement, 
behavioural or psychological measures.  
The high attrition rate shown in Figure 2 was not anticipated in the sample size calculation and could be 
addressed in future work by utilising the established 20% attrition rate used in clinical trials. 
Furthermore it was not possible to derive a meaningful correlation between treatment compliance and pain 
response due to small sample size and poor protocol compliance for use of TSCORE and TLOG. This is an 
important measurement to be considered in future research utilising time linked electronic measurement 
devices. 
 
Another explanation for under-use of TENS was that some patients did not experience pain relief and may 
have lacked motivation to continue using it.  In contrast, the majority of cases of non-compliance with the 
prescribed 1-hour duration of TENS treatments were due to patients using TENS for longer than the 
specified time.  Some patients said that when TENS was relieving their pain they chose not switch the 
machine off after an hour while others reported that they often forgot to switch TENS off. The latter 
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situation more likely reflects clinical practice.  An alarm or built-in timer to stop stimulation could overcome 
this problem for research studies demanding that TENS is used for prescribed periods of time. In clinical 
practice there is debate regarding alarm use since some commentators believe that TENS should be used in 
prescribed regimens whereas others do not (25).   
 
     Overall compliance in using TSCORE to make the prescribed number of pain reports was rather poor 
with 37% of participants reporting fewer than half the required number of pain scores. The most likely 
explanation for this is that participants forgot to use TSCORE at the prescribed times and this was confirmed 
by patient report. A possible explanation for poor compliance with the protocol was that initial training in 
TENS-use and pain reporting was insufficient.  However at the first study visit, TENS-use, electrode 
placement and TSCORE were demonstrated and patients had the opportunity to practise using the equipment 
before taking it home.  Full verbal and written instructions and contact details were given and patients were 
asked if they understood what they were being asked to do.  The provision of written and verbal instructions 
and a telephone contact is common to other studies testing the efficacy of TENS for chronic pain (27, 19, 28, 
29).   In some of these studies (27, 29) patients used paper diaries to record TENS-use and these data were 
used as evidence of high compliance with the trial protocols.  However Stone et al. (17) demonstrated that 
paper diary data is unreliable as there is no record of time of report.  In the study by Lewis et al., (19), 
patients were required to use TENS for 30-60 minutes ≥3 times daily for 3 successive 3-week phases.   
Electronic data monitoring was used and compliance with the pain score reporting protocol was found to be 
88%.  Such high compliance might have resulted from an audible alarm prompting pain reporting 4 times 
daily.  These findings suggest that the implementation fidelity of future TENS research could be improved 
by using reminders to help participants adhere to TENS-use and pain reporting protocols.  The issue of 
training is an important one and there is an absence of literature relating to the adequacy of training in 
TENS-use and its association with compliance. 
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       The novel and innovative aspect of this study was the use of electronic data logging devices to time-link 
pain report to TENS-use and allow participants to be classified as TENS-responders or non-responders.  
Data monitoring in the current study showed a ≥30% reduction in pain scores within 30-60 minutes of 
starting TENS in 86% of responders, which is in good agreement with previous studies investigating 
analgesia onset (5, 7).  Using a ≥30% reduction in mean pain scores from baseline to any prescribed pain-
reporting time point to define response, 42% of participants were TENS-responders.  However, this outcome 
should be interpreted with the proviso that more than three quarters of participants adhered only partially to 
the study protocol, the use of data monitoring devices prove the 42% responder finding is not robust.  It is 
precisely this information that has been missing from previous TENS research.  The use of data monitoring 
will allow implementation fidelity of future studies to be assessed and findings to be weighted accordingly. 
In interpreting the TENS response findings the use of only one TENS channel could have reduced response 
rates compared with the use of two channels. In addition, coverage of the TENS sensation over the back 
might not have been maximal or optimised and this factor is a limitation of our study. 
    
      A further research application for TLOG and TSCORE is the facilitation of enriched enrolment 
randomised withdrawal (EERW) designs.  Conventional RCTs are vulnerable to Type II errors in failing to 
show analgesic efficacy where it actually exists because RCTs report mean outcomes, averaging genuine 
benefit derived by responders with absence of benefit in non-responders. This is not representative of the 
true situation because few patients have an ‘average’ response to analgesia (30); consequently there is a 
move towards EERW designs (31, 32, 33, 34).  These are 2-stage designs where treatment-responders are 
identified and selected in stage 1.  Only those responding to treatment in stage 1 are randomised to receive 
active intervention or placebo in stage 2.  The use of data monitoring devices provides objective evidence 
allowing TENS-responders to be identified and compliance with the protocol to be assessed.  We are not 
aware of any clinical TENS trials using EERW, but its use would allow TENS efficacy to be evaluated with 
greater assay sensitivity.  The use of TENS data monitoring devices also has clinical application in screening 
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patients to identify those deriving clinically important benefit from TENS and those for whom assistance 
with implementation has potential to increase benefit.   
 
     In this study three TLOG devices failed due to faulty components supplied by the manufacturer and one 
TSCORE device failed due to a design problem. These problems were rectified and did not recur.  
The detection of TENS electrical output by TLOG was highly robust and allowed detailed compliance data 
to be recorded irrespective of patient applied waveform characteristics.  Where patients selected non-
therapeutic amplitude settings of less than one on the TENS dial (i.e. machine just turned on) the TLOG 
algorithm was configured to record detailed timing of treatment session but not amplitude, frequency and 
pulse duration settings. Possible reasons for low amplitude measurement and selection are: fear of electrical 
currents, dislike of paraesthesia, poor understanding of how to use TENS, or TENS worsening the pain but 
patient still trying to adhere to the protocol to please the investigator.  Other less likely reasons might 
include very low patient impedance or electrode shorting.  
 
     It was found that only 4/14 responders used TENS on 13 or 14 days, as required by the TENS-use  
protocol and so it was not possible to correlate TENS amplitude, frequency or pulse width measurements 
with therapeutic response for such a small sample size. Two of these responders had no pain relief 
medication and two were taking an analgesic. It should be noted that medication diaries were kept to 
monitor pharmaceutical treatment and this could have influenced patient views regarding the value of the 
TENS intervention.  
 
    All patients received continuous mode stimulation so that numerical processing requirements and power 
consumption for TLOG could be minimised. Further study would be required to determine if this restriction 
influences compliance and pain outcomes. 
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     TENS applied voltage waveform to in-vivo human skin exhibits a non-linear relationship with stimulation 
current (35), resulting in asymmetrical distortion of the applied rectangular voltage waveform. This led to 
inaccuracies in pulse duration measurement and hence these data were not analysed. For the TENS machines 
used, the rise and fall times of the voltage waveform were extended when applied to patients. TLOG used 
the leading edge and falling edge from the base of the assumed rectangular voltage waveform to calculate 
duration. Recordings indicated that a large proportion of pulse duration measurements exceeded the 250uS 
eight bit measurement capability of TLOG. This resulted in a discrepancy between the TENS dial markings 
and the measured TLOG values. TLOG recorded the peak voltage of the rectangular pulse. This method was 
chosen so that “TENS switch on” and “TENS switch off” events could be robustly detected irrespective of 
patient electrode connectivity and impedance issues associated with self-administered field use. It also 
simplified device design and allowed for increased battery life. Calculation of TENS current is dependent on 
knowing electrode and patient impedance but these were unknown and can vary widely during treatment. A 
revised model of TLOG now incorporates additional circuitry for the measurement of current waveform 
characteristics for use in future work. 
 
     Temporal recording of TENS parameters and electronic pain scores has not been widely adopted by 
manufacturers since it provides no immediate clinical benefit and increases the cost of treatment equipment.  
However, more expensive equipment can be justified for research purposes where TENS treatment can be 
studied and optimised for future patient benefit. 
 
     TENS devices, with three adjustable parameters could be too sophisticated for some patients which might 
influence willingness to use the devices. Device simplification could be addressed by restricting frequency 
(low/high) and pulse duration parameters. Temporal recording of pain scores and TENS machine output 
monitoring could be used in clinical trials to optimise and validate applied restrictions in addition to 
providing reliable adherence data. 
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     This observational work suggests that study findings are potentially unreliable when interventions are 
self-administered in unsupervised settings without adequate monitoring. However, further work might be 
required to dichotomise TENS therapy into supervised and unsupervised applications to determine if there is 
a significant difference in outcomes and patient fidelity. The impact of this study is broader than TENS 
research; treatment fidelity is important in all pharmacological and non-pharmacological trials, which 
emphasises the need for implementation-monitoring. 
 
     Bjordal (36) calls for urgent action to address the problem of low fidelity in studies assessing the efficacy 
of TENS and other physical interventions for pain relief. The use of TLOG and TSCORE together has 
allowed pain report to be time-linked to TENS-use and compliance with the study protocol to be determined.  
It has shown pain relief to occur during TENS, highlighting the importance of assessing outcome during 
stimulation.  A revised version of TLOG could monitor intensity settings selected by TENS-users, thus 
providing an indication of dosing.  This innovative approach provides an opportunity for a consensus to be 
reached on the standards required for high fidelity TENS research.  
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FIGURE LEGENDS 
FIGURE 1. Photograph showing TENS machine with TLOG device attached and one pair of electrodes; 
also TSCORE electronic pain scoring device. 
FIGURE 2. Flow chart showing: TENS-use, TSCORE-use and participant attrition during the course of the 
study. 
FIGURE 3. Number of patients reporting pain scores at any of four time points before, during and after 
TENS on at least 13 days, 7-12 days or fewer than 6 days. 
TABLE 1. Compliance with TENS implementation protocol (N=38). Timing data retrieved from TLOG 
devices 
TABLE 2. Compliance with timing of pain reports relative to TENS use (N=35). Timing data retrieved 
from TSCORE device. 
 
Supplemental Digital Content 
TABLE 3. Summed pain intensity difference(SPID) and electrical output parameters for TENS responders 
and non-responders. Medications and CLBP is shown for reference. 
FIGURE 4. Comparison of mean summed pain intensity difference(SPID) with respect to mean TENS 
voltage for responders and non-responders. 
  
                                                                                                                            Implementation fidelity of TENS 
 
23 
 
TABLE 1. Compliance with TENS implementation protocol (N=38) (Timing data retrieved from TLOG devices). 
 
Number of patients adhering to required TENS usage pattern:  (Full compliance is defined as daily TENS use for 13 or 14 days). 
Fully compliant   Partially compliant (TENS used on 7-12 days)                  Non-compliant (TENS used ≤ 6 days) 
19 (50%)    13 (34%)         6 (16%)   
  
Number of patients adhering to required TENS treatment duration: (Full compliance = Mean treatment duration of 60±10 minutes and SD≤10 minutes).  
Fully compliant   Partially compliant (Mean duration=60±10 mins, but SD>10 mins)  Non-compliant (no TENS treatments) 
 25 (66%)    11 (29%)         2 (5%)  
  
Number of patients adhering to both the required TENS usage pattern AND required TENS treatment duration:  
Fully compliant with TENS implementation protocol   Partially or non-compliant with TENS implementation protocol 
13 (34%)         25 (66%) 
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TABLE 2. Compliance with timing of pain reports relative to TENS use (N=35). Timing data retrieved 
from TSCORE devices 
 
Compliance with required timing of Baseline pain report (i.e. TENS switch-on time ±5 minutes) 
Fully compliant Partially compliant (≥1 report made outside the reporting time window)  
25 (71%)  10 (29%)        
  
Compliance with required timing of TENS_30 report (i.e. 30±10 minutes after TENS switch-on time) 
Fully compliant Partially compliant (reports outside time window) Non-compliant (no reports made) 
22 (63%)  10 (29%)      3 (8%)   
 
Compliance with required timing of TENS_60 report (i.e. 60±10 minutes after TENS switch-on time) 
Fully compliant Partially compliant (reports outside time window) Non-compliant (no reports made) 
20 (57%)  13 (37%)      2 (6%)    
 
Compliance with required timing of post_TENS report (i.e. 30±10 minutes after TENS switch-off time) 
Fully compliant Partially compliant (reports outside time window) Non-compliant (no reports made) 
11 (32%)  20 (57%)      4 (11%) 
 
Compliance with required timing of all reports (Baseline and TENS_30 and TENS_60 and post_TENS)  
Fully compliant (all reports as per protocol) Partially compliant  Non-compliant (Baseline scores only) 
2 (6%)      31 (88%)  2 (6%) 
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TABLE 3.Summed pain intensity difference (SPID) and electrical output parameters for TENS  
responders and non-responders.  Medication(s) and CLBP duration is shown for reference.  
1Responder classified as >=30% reduction in mean pain score from baseline at time points T30, T60 and PoT.  
 
 
 
 
 
 
 
 
1Responder classified as >=30% reduction in mean pain score from baseline at time points T30, T60 and PoT.  
(Abbreviations No.: Number, Sess.: Sessions, Min.: Minutes, Freq.: Frequency, Dur.: Duration, Med.: 
Medication, Qty.:Quantity, Yrs.: Years) 
PI-NRS Pain intensity numerical rating scale 
 
Pat 
No 
No. of  
1 Hr 
TENS 
Sess. 
TENS 
Responder1 
Time 
TMins 
SPID 
(PI-NRS) 
(PrT-T30)+ 
(PrT-T60) 
Mean(SD), 
Peak 
Voltage 
Mean(SD), 
Peak 
/V 
Freq. 
Mean(SD) 
/Hz 
Pulse 
Dur.* 
Min 
/uS 
Med. 
Qty.Type 
CLBP 
(Yrs) 
    Responders     
20 13 PoT 1.1(1.2),3 8.5(11.3), 37.1 80.9(50.4) 64 None 1 
5 11 T60,PoT 1.9(1.9),4 30.1(8.5),50.8 21.2(12.2) 150 >1n,a,ad 5 
8 14 T30,T60,PoT 1.9(1.6),5 24.0(9.4),49.4 25.5(28.9) 213 1   >6 
10 9 T60,PoT 1.9(1.8),5 32.4(18.3),59.7 71.7(46.1) 95 None >3 
7 9 T60 2.7(1.9),6 11.3(10.8),56.4 24.0(23.0) 198 >1o,a >1 
11 12 T60 2.7(2.3),7 34.8(16.0),53.1 105(15.9) 66 None 8 
37 14 T60,PoT 2.8(1.3),5 15.0(3.76),20.7 135(46.5) 23 >1a 7 
2 n/a T30,T60,PoT 4.2(0.9),5 n/a n/a n/a >1  30 
40 14 T30,T60,PoT 4.3(3),9 12.2(3.6),21.2 84.9(29.6) 77 >1a n/a 
35 4 T60 4.5(4.4),11 8.0(12.7),33.4 n/a n/a None 2 
31 12 T30,T60 4.6(2.8),9 27.7(13.6),57.8 78.9(28) >250 >1o,n,a,at,ad 1 
13 12 T30,T60,PoT 5.8(2.8),11 4.7,(7.5),38.5 82.3(29.7) >250 None 5 
41 10 T30,T60,PoT 7.6(2.0),10 1.2(2.0),15.5 n/a >250 None n/a 
23 11 T30,T60,PoT 7.8(1.3),11 14.1(7.5),34.8 154(2.2) >250 1o,a,n(p) 7 
Non-Responders 
30 6 n/a -1(1.4),1 23.0(13.2),43.2 82.5(39.4) 56 1a 0.5 
22 14 n/a -0.5(0.9),1 10.8(7.1),23.5 98.7(37.8) 57 None 11 
12 14 n/a 0.5(1.3),3 16.9(12.2),57.3 104(50.4) 71 >1a,n,ad 2 
15 14 n/a 0.5(0.7),2 17.9(5.6),29.6 54.1(34.1) >250 None 26 
33 9 n/a 0.5(0.8),2 15.0(20.7),55.9 134(3.9) 39 None n/a 
9 13 n/a 0.6(0.9),2 40.0(9.4),52.2 113(26.5) 104 1n 2 
14 14 n/a 0.6(1.2),4 6.1(1.8),10.8 62.2(18.2) >250 None 2 
17 14 n/a 0.9(1.1),3 15.0(4.7),23.5 81.1(22.3) >250 1at 1 
27 14 n/a 0.9(1.2),3 4.0(1.6),10.8 35.5(6.84) 62 None 8 
28 6 n/a 0.9(1.5),4 12.5(3.9),16.9 101.7(34.5) 100 1o,n,a,at,ad >15 
42 14 n/a 0.9(0.9),2 10.8(6.1),50.3 84.9(9.1) 25 >1a,at n/a 
1 12 n/a 1(3.2),5 n/a 142(0.6) n/a >1a,ad 28 
24 12 n/a 1(0.9),2 7.5(3.7),18.3 129(48.6) 42 >1n,a 0.5 
26 13 n/a 1(0.9),2 16.5(9.4),32.4 99.3(60.8) 30 >1a,n 17 
38 12 n/a 1.1(1.2),4 6.1(6.1),54.1 54.1(1.0) 87 >1o,a,at 2 
36 13 n/a 1.6(0.7),3 14.1(14.6),57.8 n/a 93 1a >1 
18 13 n/a 1.7(1.6),4 13.6(6.1),38.5 128(50.8) 106 None 7 
29 14 n/a 1.9(1.1),5 22.1(10.3),32.4 65.3(8.3) 33 1o(p) 10 
39 11 n/a 2.5(2.2),6 19.7(10.3),40.9 100(29) 66 >1a,ad >7 
Excluded 
3 n/a n/a n/a# n/a n/a 142 >1o,n 20 
6 13 n/a n/a# 3.7(6.58),20.2 n/a n/a >1o,n,at 4 
21 13 n/a n/a# 10.3(3.1),16.0 21.3(15.3) 59 >1o,a,ad 12 
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PI-NRS measurement time coded as :- 
PrT: Pre_TENS baseline, T30 : TENS_30, T60:TENS_60, PoT:post_TENS. 
Rows sorted for increasing SPID 
#Insufficient TSCORE data for response classification 
*In all patients maximum pulse width extends beyond 250 uS 
Medications: aAnalgesic, nNSAID, oOpiate, atAtypical analgesic (Gabapentin, pregabalin), adAntidepressant, 
(p)Patch 
(Other medications for BP, Diabetes etc. not coded) 
 
Pain intensity difference PID values were determined from pain scores by subtracting TENS_30 and 
TENS_60 from the pre-TENS baseline score respectively. These were summed to obtain SPID for each 1 
Hour TENS therapy session. (Please note post_TENS was not included in SPID calculation) The mean, SD 
and peak SPID are shown in table 3 sorted in ascending order for comparison with TENS machine electrical 
characteristics which include voltage (mean, SD and peak), frequency (mean and SD) and pulse width range 
(minimum to >250uS). These descriptive statistics were derived from raw values recorded by TLOG for 
each TENS treatment session. Medication classification and length of CLBP illness provide a clinical 
context. 
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